Are you Dr. Nowak?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 25 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1000 E Mountain Blvd
Wilkes-Barre, PA 18711Phone+1 570-825-1000Fax+1 570-271-6578
Summary
- Dr. Miroslawa Nowak, MD is a rheumatologist in Wilkes-Barre, Pennsylvania. She is currently licensed to practice medicine in Pennsylvania.
Education & Training
National Institutes of Health Clinical CenterFellowship, Rheumatology, 2000 - 2003
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1996 - 1999
Pomeranian Academy of Medicine in SzczecinClass of 1990
Certifications & Licensure
PA State Medical License 2003 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
- Fellow (FACR) American College of Rheumatology
Publications & Presentations
PubMed
- Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: Achievement of minimal disease activity components in a phase 2 trial.Arthur Kavanaugh, Laura C Coates, Philip J Mease, Miroslawa Nowak, Lauren Hippeli
Rheumatology. 2024-10-18 - Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses.Oliver FitzGerald, Dafna D Gladman, Philip J Mease, Christopher Ritchlin, Josef S Smolen
Arthritis & Rheumatology. 2024-09-01 - 1 citationsImprovements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial.Vibeke Strand, Laure Gossec, Laura C Coates, Alexis Ogdie, Jiyoon Choi
Arthritis Care & Research. 2024-08-01
Authored Content
- Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled TrialOctober 2020
Professional Memberships
- Fellow
